Certara

70 articles about Certara

• Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

  11/7/2022

  Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, has committed to make a new $449M investment in Certara.

• Certara to Participate in Upcoming November 2022 Investor Conferences

  11/2/2022

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

• Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions

  10/19/2022

  Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ Simulator, Phoenix™ biosimulation software, and Pinnacle 21™ Enterprise software.  

• Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

  10/13/2022

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022.

• Certara to Participate in Upcoming Investor Conferences in September 2022

  8/31/2022

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

• Certara Announces Secondary Offering - Aug 11, 2022

  8/11/2022

  Certara, Inc., a global leader in biosimulation, announced the sale by certain stockholders, including EQT Avatar Parent L.P., in an underwritten secondary offering of 7,000,000 shares of common stock of Certara pursuant to a registration statement filed by Certara with the U.S. Securities and Exchange Commission.

• Certara Reports Second Quarter 2022 Financial Results

  8/9/2022

  Certara, Inc., a global leader in biosimulation, reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance.

• Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module

  8/5/2022

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s flagship software for validating clinical trial data for biosimulation and regulatory submissions.

• Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell TherapiesCertara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies

  7/28/2022

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop new biosimulation software. Certara will be working with the MSK Innovation Hub to create a Chimeric antigen receptor (CAR) T-cell therapy biosimulation platform.

• Certara Appoints Rosemary Crane as New Independent Board Member

  7/25/2022

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022.

• 

  Sanofi, Pfizer and More Use Upskilling to Solve the Life Science Talent Shortage

  7/13/2022

  Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.

• Certara Appoints Eran Broshy as New Independent Board Member

  7/13/2022

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022.

• Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

  7/12/2022

  Certara, Inc., a global leader in biosimulation, announced that it will release financial results for the second quarter of 2022 after the market close on Tuesday, August 9th, 2022.

• Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

  6/28/2022

  Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research.

• Certara Reports First Quarter 2022 Financial Results

  5/5/2022

  Certara, Inc., a global leader in biosimulation, reported its financial results for the first quarter of fiscal year 2022.

• Certara to Participate in Upcoming Investor Conferences in May 2022

  5/3/2022

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

• Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

  4/20/2022

  Certara, Inc. today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022.

• Certara Reports Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  Certara, Inc., a global leader in biosimulation, reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022.

• U.S. FDA Licenses Certara’s Immunogenicity SimulatorAffirms the advancements of innovative biosimulation technology and its growing impact in R&D

  2/23/2022

  Certara, Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator predicts the immune response of therapeutics in development, which is important to guide clinical and regulatory decision-making.   

• Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

  2/15/2022

  Certara, Inc., a global leader in biosimulation, announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Review were received by Certara’s customers in 2021, excluding diagnostic agents.